Last reviewed · How we verify
IL-1 Trap
At a glance
| Generic name | IL-1 Trap |
|---|---|
| Sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Injection site erythema
- Diarrhoea
- Nasopharyngitis
- Arthralgia
- Myalgia
- Headache
- Cough
- Injection site pruritus
- Injection site swelling
- Back pain
- Pyrexia
- Musculoskeletal chest pain
Key clinical trials
- Rilonacept in Subjects With Cardiac Sarcoidosis (PHASE2)
- A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis (PHASE2)
- Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis (PHASE3)
- A Pilot Study of KPL-914 in Recurrent Pericarditis (PHASE2)
- Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra) (PHASE2)
- An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes (PHASE3)
- Cold Contact Urticaria Treatment With Rilonacept (PHASE2)
- Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |